Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.

Current treatment options in oncology - 1 Mar 2017

Abdelaziz Ahmed, Vaishampayan Ulka

Abstract excerpt

OPINION STATEMENT: Cabozantinib was approved by the FDA in April 2016 for the treatment of advanced renal cancer, pretreated with at least one prior antiangiogenic therapy. This is the first agent in the therapy of kidney cancer to show a statistically significant improvement in all three endpoints of clinical efficacy, response rate, progression free survival, and overall survival (OS), in a phase III randomized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Carcinoma, Renal Cell
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Drug Discovery

Share to Kidney Neoplasms

Share to Pyridines

Share to Retreatment

Source

Open in PubMed Open full text

Identifiers

PMID: 28286925
DOI: 10.1007/s11864-017-0444-6
PMCID: PMC6854754

Genes

HGF
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.PMID 28286925Read ↗

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.Semantic proximity Read ↗

Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-CarcinomaSemantic proximity Read ↗

Current and future strategies in nonclear-cell metastatic renal cell carcinoma.Semantic proximity Read ↗

Molecular basis for the treatment of renal cell carcinoma.Semantic proximity Read ↗

Kidney cancer pathology in the new context of targeted therapy.Semantic proximity Read ↗

Current updates and future perspectives on the management of renal cell carcinoma.Semantic proximity Read ↗

Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: A network meta-analysisSemantic proximity Read ↗

Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.Semantic proximity Read ↗

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.Semantic proximity Read ↗

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.Semantic proximity Read ↗

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.Semantic proximity Read ↗

Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.